## UHS: Universal Health Services, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.6% below STRENGTH zone (3.0-6.0%); PEG 1.87 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($210.30)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. VIRGINIA RETIREMENT SYSTEMS ET Al Sells 79,700 Shares of Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251231T170805 | Neutral | Relevance: 100%
- Virginia Retirement Systems Et Al reduced its stake in Universal Health Services, Inc. by 16.5% during the third quarter, selling 79,700 shares. Despite this institutional selling, other major funds increased their positions, and Universal Health Services reported strong quarterly earnings, beating analyst estimates with $5.69 EPS and $4.50 billion in revenue. Analysts have raised price targets, maintaining a "Hold" consensus with an average target of $234.14 for UHS.

**2. Universal Health Services Inc. Cl B stock underperforms Wednesday when compared to competitors**
- Source: MarketWatch | 20251231T163000 | Bearish | Relevance: 100%
- Shares of Universal Health Services Inc. Cl B (UHS) fell 3.13% to $218.02 on Wednesday, making it the third consecutive day of losses for the stock. This underperformance occurred during a broader market decline, with the S&P 500 Index (SPX) dropping 0.74% and the Dow Jones Industrial Average (DJIA) falling 0.63%.

**3. Federal judge puts brakes on new 340B drug rebate program (NYSE:HCA)**
- Source: Seeking Alpha | 20251231T173241 | Somewhat-Bullish | Relevance: 71%
- A federal judge in Maine has temporarily blocked the implementation of a new 340B drug rebate program for hospitals, which was scheduled to start on January 1st by the Trump administration. The judge noted that the pilot program was "rather threadbare." This decision affects companies like HCA Healthcare (NYSE:HCA), Universal Health Services (UHS), Community Health Systems (CYH), and Tenet Healthcare (THC).

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($11.07M) |
| Sells | 3 ($30.51M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-3.4%)
- First Eagle Investme: 8.4% (+0.0%)
- Blackrock Inc.: 8.0% (-11.9%)
- State Street Corpora: 4.7% (-3.1%)
- FMR, LLC: 3.8% (+0.1%)

### Key Risks

1. Heavy insider selling: $31M sold (3 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.87 elevated, pricing in significant growth expectations. Insider selling cluster ($30.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.0B |
| Beta | 1.27 |
| 52W Range | $152.33 - $246.33 |
| Short Interest | 5.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.87 |
| Forward P/E | 9.4 |
| Current P/E | 10.1 |
| YoY Growth | 8.0% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -0.5% to -1.6% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.6pp (needs >3.0% for momentum thesis). Underperforming sector by 3.3pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.14x) but short-term weakness (below SMA20). MACD histogram bearish (-0.96), momentum weakening. RSI neutral at 40. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.63% (CS: 16) | Neutral |
| RSI_14 | 40.1 | Neutral |
| MACD Histogram | -0.96 | Bearish |
| vs SMA20 | 0.976x | Below |
| vs SMA50 | 0.973x | Below |
| vs SMA200 | 1.136x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $219.88
- **Stop Loss:** $210.30 (4.4% risk)
- **Target:** $229.46 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 150
- **Position Value:** $32,982.00
- **Portfolio %:** 32.98%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-25 (Est: $5.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.95 | $5.69 | +14.9% |
| 2025Q2 | $4.96 | $5.35 | +8.0% |
| 2025Q1 | $4.36 | $4.84 | +11.1% |
| 2024Q4 | $4.18 | $4.92 | +17.8% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*